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Summary
Nephrolithiasis is a multisystem disease arising from the sin-
ergic effects of enviromental, hormonal and genetic factors. In
Europe an incidence of 2000 stones per million of population
has been reported. Kidney stones are mainly composed of
calcium (70-80%) with a predominance of calcium oxalate,
with or without calcium phosphate. Low urinary citrate excre-
tion is a common feature of idiopathic calcium stone disease.
A wide range of hypocitraturia prevalence in nephrolithiasis
have been reported in literature. Hypocitraturia is defined as a
urinary citrate excretion lower than 320 mg/day. Many factors
can modulate citrate excretion. Among them an important role
is played by acid-base status, nutritional factors, strarvation,
hormones and drugs. Estrogen exert an important modulating
effect on urinary citrate excretion. Several authors, in fact,
have described a reduction in urinary citrate excretion in
healthy postmenopausal women, as well as a lower citraturia
in males than in premenopausal females. Urinary citrate di-
rectly inhibits stone formation by forming highly soluble com-
plexes with calcium in the renal tubule and by increasing in-
traluminal pH. Idiopathic calcium stone disease, but also other
forms of nephrolithiasis, as well as some other pathological
conditions can be treated with alkaline citrate. The most com-
mon form of these salts is potassium citrate that has been
successfully used in the prevention of stone recurrence. In
conclusion alkaline citrate represents an effective tool in the
prevention of calcium stone formation. Last, but not least, this
form of therapy presents few side effects.
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Introduction and physiological elements
Nephrolithiasis is a multisystem disease arising from the siner-
gic effects of enviromental, hormonal and genetic factors. The
annual incidence of renal stones is between 0.1 and 0.4% and
nephrolithiasis shows wide geographical variations (1-3). In Eu-
rope an incidence of 2000 stones per million of population has
been reported (4). The lifetime risk of stone formation ranges
between 5 and 10% with an expected recurrence rate of almost
50% (4). Up to 70-80% of patients have calcium-containing
stones with a predominance of calcium oxalate (CaOx), with or
without calcium phosphate (CaP) (5). 
Citrate is a weak acid, with a molecular weight of 189 KDa, that
is synthesized in the Krebs cycle starting from the condensa-
tion of acetyl-CoA and oxalacetate, or that may derive from ex-
ogenous intake. In plasma and in urine (although to a lesser
degree) citrate is present mainly as a trivalent anion citrate–3;
whereas, when the pH becomes more acidic the divalent form
of anion citrate–2, increases significantly (6). 
The mean daily intake of citrate with the diet is 4 grams and its
intestinal absorption is rapid and almost complete. 
Plasma citrate is filtered by the kidney and then reabsorbed, in
the proximal tubule mainly in the convoluted and straight seg-
ments; in contrast tubular reabsorption does not seem to be
present either in the thick ascending tract of Henle limb or in
the cortical collecting duct (6). Citrate proximal tubular reab-
sorption involves a sodium dependent dicarboxylate trans-
porter that permits the reabsorption across the apical mem-
brane where the citrate is reabsorbed mainly as dicarboxylate
anion, although the tricarboxylate is the more common form
(7). Furthermore, experimentally in cell culture, a new sodium
dependent saturable citrate transport was observed involving a
trycarboxylate transporter; in vivo, this trycarboxylate citrate
transporter may be located on the basolateral membrane (8). A
rate of 10-35% of the filtered load is excreted in the urine. The
citrate reabsorbed from the proximal tubule and a small quota
deriving from peritubular vessels contribute to the energy sup-
ply of the kidney. In fact this ion, via a complete oxidation in the
mitochondrial Krebs cycle, participates in the production of
ATP. Another destiny of citrate is cytosolic metabolization into
Acetyl-CoA and oxalacetate by means of the enzyme ATP cit-
rate lyase (9). The small intestine presents a citrate transporter
similar to the sodium dependent dicarboxylate carrier observed
in the proximal renal tubule; at least experimentally, entero-
cytes seem to present a secretion mechanism of citrate (9). Af-
ter oral intake of alkaline salts, citrate undergoes intestinal ab-
sorption and is metabolized inducing an alkaline load that in-
creases the urinary citrate excretion (9). A reduced intestinal
alkali absorption may cause a hypocitraturia condition (10).
Hypocitraturia is one of the main factors associated with idio-
pathic kidney stone disease. Moreover citrate has been widely
studied for its action in preventing renal stones and it has
showed a very high efficacy against calcium nephrolithiasis
(11-13). Many physiological conditions, several drugs and
some diseases modulate urinary citrate excretion as shown in
table I. Acid-base state is one of the main regulators of urinary
citrate excretion, with metabolic acidosis inducing hypocitra-
turia. Also potassium depletion plays an important role in de-
creasing urinary citrate excretion. Both these conditions en-
hance ATP citrate lyase activity in the cytosol of renal cortex
cells, thus leading to a decreased intracellular citrate concen-
tration and, ultimately, to an increased reabsorption of this ion
at the brush border membrane level (9,14). One of the hor-
mones that exerts an important modulating effect on urinary cit-
r te excretion is estrogen. Several authors, in fact, have de-


















scribed a reduction in urinary citrate excretion in healthy post-
menopausal women, as well as a lower citraturia in males than
in premenopausal females (9).
Urinary citrate directly inhibits stone formation by forming high-
ly soluble complexes with calcium in the renal tubule. The first
effect of this complex is to reduce urinary levels of supersatura-
tion with CaOx and CaP (4,9). Moreover citrate reduces the
spontaneous nucleation, the agglomeration, the aggregation
and the crystal growth of CaOx and CaP (9). It could be said
that citrate acts as a ÒpoisonÓ on renal stones.
Hypocitraturia: the magnitude of the problem
Low urinary citrate excretion is a common feature of idiopathic
calcium stone disease. Several cut-off values have been pro-
posed to classify hypocitraturia (9). In 1983, Nicar et al. (15)
defined hypocitraturia as a 24 hour citrate excretion lower than
320 mg (or 1.7 mmol) while other authors fixed the limit below
the normal range (12,16-18). These different cut-off values
may account for the wide range of hypocitraturia prevalence in
nephrolithiasis, since it varies from 8% up to 68.3% in the liter-
ature reports (Table II). Another factor which may account for
these difference in prevalence is the possibility of considering
hypocitraturia as a single metabolic alteration. In fact in a previ-
ous paper we found a hypocitraturia frequency, considered as
a single metabolic derangement, of 12%, whereas, when con-
sidering hypocitraturia together with hypercalciuria and/or hy-
peruricosuria, this rate increased to 32% (19). Last but not
least, the evaluation of urinary citrate excretion is highly influ-
enced by food intake. Therefore a relevant difference in daily
citrate excretion will occur according to whether patients are on
their home diet or on controlled diet (9).
A commonly accepted limit under which hypocitraturia may be
diagnosed has been proposed by Pak. This Author suggested
a “functional” definition of hypocitraturia which is a citrate ex-
cretion lower than 320 mg/day (20).
Notwithstanding the cut-off value adopted, several authors
have described a higher rate of hypocitraturia in recurrent
stone formers (41%) than in single stone formers (29%), as
well as a higher urinary citrate excretion in pre-menopausal fe-
males than in males and menopausal females (9).
The daily urinary citrate to calcium ratio has also been used as
a risk factor for stone formation. In fact it has been observed
that patients with hypocitraturia, as a single metabolic alter-
ation, showed higher urinary citrate excretion than those with
several metabolic abnormalities. Moreover a higher rate of
hypocitraturia was present also in stone formers with a very ac-
tive calcium stone disease and/or low urinary citrate/calcium
ratio (21-23). Welshman and McGeown found a calcium/citrate
ratio in stone formers and normal subjects of 4.52 and 3.02 re-
spectively, while in stone forming females this ratio was 3.54
and 1.41 in healthy females (17). Similar results were obtained
in successive studies (9). Finally, Parks et al. examined the cit-
rate/calcium ratio in 13 studies in which patients were man-
tained on their home diet, and they found a clear difference be-
tween renal stone formers and healthy subjects (24). Stone-
forming females had higher urinary calcium and lower citrate
than control females, whereas stone forming males presented
a significantly higher urinary calcium excretion than normal
subiects but only a small decrease in citrate excretion. Further-
more, also the studies in which the patients ate controlled di-
ets, showed, generally, a lower urinary citrate excretion in
stone formers than in healthy subjects and these differences
persisted when the subjects were considered separately ac-
cording to sex (24). Finally, also in a recent paper (25), dealing
with hypercalciuria and bone mass, we have found a higher uri-
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Table I - Effect of different factors on urinary citrate excretion.
Factor Citraturia









› Animal proteins fl









Transport competitors (succinate, malate, fumarate)›
Metabolic inhibitors (fluorocitrate, malonate, maleate)›
Distal renal tubular acidosis fl
Chronic renal failure fl
Inflammatory bowel diseases fl
By-pass or ileal resection fl
Diarrhea and/or malabsorption fl
Strenous exercise (lactic acidosis) fl
› = Increase; fl = Decrease
Table II - Reported prevalence of hypocitraturia in patients with
nephrolithiasis.
Authors Prevalence Year
Jaeger et al. 18.0% 1986
Caudarella et al. 12.6% 1986
Hess et al. 29.0% 2002
Hosking et al. 29.2% 1985
Khand et al. 29.2% 1994
Mossetti et al. 32.7% 2003
Caudarella et al. 32.8% 1996
Höbart and Hofbauer 34.0% 1991
Akinci et al. 46.6% 1991
Vahlensieck et al. 47.0% 1987
Pak et al. 50.0% 1987
Nicar et al. 55.0% 1983
















nary citrate excretion in females than in males (p=0.019) and
the prevalence of hypocitraturia in the whole population was
25.5% (unpublished data).
Citrate salts in the treatment of nephrolithiasis
Several studies have pointed out that alkaline citrate is one of
the most efficient therapeutic regimens in the treatment of idio-
pathic calcium nephrolithiasis. In 2001 the Advisory Board of
European Urolithiasis Research recommended alkaline citrate,
thiazides and fluid intake as the corner-stones in preventing
calcium stone formation (26). Oral citrate administration results
in an alkali load that, in turn, increases urinary citrate excretion
by means of a reduction in the tubular reabsorption of this ion
(9). The consequent high urinary citrate concentration and the
alkalinization of the urine cause several effects that struggle
against CaOx and CaP crystallization (4). The increased intra-
luminal pH induces a dissociation of citrate and the inhibitory
macromolecules, resulting in an enhanced inhibiting power. For
example, it has been suggested that Tamm-Horsfall protein
(THP) shows a dichotomous behaviour on stone formation, act-
ing either as promoter or as an inhibitor of crystallization
processes. When urinary citrate increases and luminal pH ris-
es, THP viscosity decreases and its inhibitory effect on calcium
oxalate aggregation is enhanced. On the contrary in the ab-
sence of citrate THP promotes calcium oxalate aggregation (9). 
As far back as 1985 Preminger et al. demonstrated that new
stone formation continued in 39% of the patients during conser-
vative or placebo trials and 69% of untreated stone formers
however, needed at the end surgical treatment. On the other
hand only 2% of the patients receiving alkaline citrate required
further surgical treatment (27). In the last two decades alkaline
salts have been widely used in patients with recurrent calcium
stone disease and in several other pathological conditions asso-
ciated or not with calcium stones (Table III). The most common-
ly used salts are potassium citrate, sodium-potassium citrate,
potassium-magnesium citrate and calcium citrate, although
potassium citrate is usually the preferential treatment (9). 
Both potassium citrate and sodium-potassium citrate, in fact,
can ameliorate urinary composition, but the sodium load in-
duced by the latter can increase calcium excretion or a less
pronounced reduction of calciuria. In fact citrate has shown to
be able to reduce urinary calcium excretion (4). Furthermore, in
p tients with hypertension, sodium intake must be restricted,
as well as in patients with calcium oxalate lithiasis treated with
thiazide. In fact, sodium load induces a hypercalciuria that is
uncontrollable with thiazide (9).
Magnesium is and inhibitor of CaP crystal growth and the com-
plexing of magnesium and oxalate induces a decrease in the
supersaturation with respect to CaOx. Nevertheless it has been
observed that also magnesium excretion is associated with an
increased calcium excretion, thus reducing the inhibiting effect
of potassium-magnesium citrate on stone formation. Moreover
long-term studies on potassium-magnesium citrate administra-
tion are still lacking. However this alkaline citrate appears to
enhance thiazide effect on urinary calcium reabsorption when
this drug is co-administered. Long-term thiazide therapy, in
fact, may result in decresead plasmatic and urinary magnesium
and in this very case magnesium supplements appear to be of
value (4). Finally promising results have come from Ettinger et
al. which found that potassium-magnesium citrate is effective in
preventing calcium oxalate stone recurrence (28).
Calcium citrate is generally prescribed as a calcium supple-
ment in the treatment of osteoporosis, while it is not usually
used for calcium lithiasis therapy. Calcium citrate increases
both urinary citrate and calcium excretion. Notwithstanding the
growth of calciuria, this compound provides an alkali load,
which in turn counteracts the increased calcium excretion.
Thus the risk of stone formation does not appear to be en-
hanced. Therefore calcium citrate seems to induce a lower risk
of stone formation than all the other calcium supplements (9).
Most of the studies on renal stone prevention have been con-
ducted using potassium citrate as alkaline salt (4). A decrease
n urinary calcium concentration has been well documented
with this drug (9). In a previous work we were able to demon-
strate the ability of potassium citrate to decrease urinary calci-
um excretion after 9 months of therapy (19), but the same re-
sult was not confirmed in a successive paper, where the follow
up period was extended to 48 months. In fact, after an increase
in urinary calcium excretion during the first year of therapy, cal-
ciuria began to decrease slowly, but progressively, in the follow
up (29). This result is in agreement with Fuselier et al., who ob-
served a small, but significant, decrease in urinary calcium ex-
cretion during treatment periods (30). Ali Tekin et al. evaluated,
in an open clinical trial, the effects of oral potassium citrate
therapy (22 months) in children with calcium stones and hypoc-
itraturia; these Authors confirmed that potassium citrate re-
duces the recurrence of renal stones and seems to be a safe
treatment. These Authors too, found a decrease in urinary cal-
cium excretion although it remained within the normal range in
most cases, so they concluded that potassium citrate seems to
influence, to a low degree, calcium excretion (31).
Moreover, in our paper, basal values of citraturia were lower
than follow up values (29). However, when patients were sub-
dived according to urinary citrate excretion, those with the low-
est basal citraturia (citraturia lower than 320 mg/24 hours) be-
haved differently. In fact after a rise in the first year, urinary cit-
rate excretion returned to values similar to or lower than basal
value. Also Fuselier et al. observed that in 21% of patients
treated with potassium citrate, urinary citrate excretion did not
rise. The Authors stated the need for a careful follow-up of the
patients treated with potassium citrate in order to identify pa-
tients requiring a more aggressive medical therapy and to
properly modify the dose of alkali salts (30). 
Oxalate, uric acid and creatinine excretion as well as urine vol-
ume do not change during the follow up of patients treated with
potassium citrate. Moreover potassium citrate does not usually
induce an increase in the relative supersaturation ratio of
brushite, as it reduces urinary calcium excretion, although an
excessive amount of potassium citrate may increase the rela-
Citrates in kidney stones
Table III - Indications for alkali citrate therapy in different diseases
and conditions.
– Idiopatic calcium oxalate stone disease (with or without hypoci-
traturia)
– Uric acid nephrolithiasis
– Mixed nephrolithiasis (hyperuricosuric calcium nephrolithiasis)
– Cystine nephrolithiasis
– Primary or secondary hyperoxaluria
– Hypocitraturia in distal renal tubular acidosis
– Hypocitraturia associated with inflammatory bowel diseases
– Hypocitraturia associated with by-pass or ileal resection
– Hypocitraturia associated with chronic diarrhea syndrome
– Drug-induced hypocitraturia
– Hypocitraturia associated with potassium depletion
– Hypocitraturia associated with excessive dietary acid load
– Residual renal stone fragments after extracorporeal shock wave
lithotripsy
– Osteoporosis (?)
















tive supersaturation ratio of brushite (9).
Furthermore, in patients with distal renal tubular acidosis,
potassium citrate treatment appears to improve calcium bal-
ance. In fact it increases intestinal calcium absorption by
means of a 1,25(OH)2D3 independent mechanism and reduces
urinary calcium excretion. According to some authors, the de-
creased calcium excretion can be explained by an increased
calcium reabsorption in the distal tubule induced by metabolic
alkalosis (32) as well as by the increased luminal pH (33). The
chronic treatment with potassium citrate and other alkaline
salts may result in a positive calcium balance. In fact a small
but significant increase in bone mineral density in stone form-
ing females has been shown (34). Also Sebastian et al., after
treating a group of healthy postmenopausal women with potas-
sium bicarbonate, observed an improved calcium balance
through an interaction of bone remodelling phases (35).
Several studies in vitro showed that citrate inhibits struvite for-
mation. In fact it causes the chelation of magnesium, the dis-
ruption of the hydrogen and ionic binding of this mineral and
the coating of the surface of struvite crystal (9).
In conclusion alkaline citrate seems to be a rational approach
to the treatment of nephrolithiasis in patients with or without
hypocitraturia, as it reduces some risk factors involved in stone
recurrence. Moreover this form of therapy presents a small
number of side effects, mainly gastro-intestinal symptoms (e.g.
diarrhea and nausea) and in very few cases hyperkaliemia.
About the safety of potassium citrate supplementation there is
a general agreement in literature; however Coe et al. report
some experimental papers showing that citrate increases in-
testinal absorption of some metals such as aluminum and lead
(36). These Authors suggest renal function in patients with re-
nal failure should be carefully evaluated to avoid an increased
intestinal absorption of aluminum, particularly if they are treat-
ed with aluminum antacids. The same precautions may be of
some use also in patients with renal stones.
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